Characterising individual response to mepolizumab treatment

被引：0
|
作者：
Jackson, David [1 ,2 ]
Price, Robert G. [3 ]
Yancey, Steven W. [4 ]
Buhl, Roland [5 ]
Wenzel, Sally [6 ]
机构：
[1] Kings Coll London, Guys Severe Asthma Ctr, Guys & St Thomas NHS Trust, London, England
[2] Kings Coll London, Sch Immunol & Microbial Sci, Asthma UK Ctr, London, England
[3] GSK, Biostat, Stevenage, Herts, England
[4] GSK, Resp Therapeut Area, Res Triangle Pk, NC USA
[5] Mainz Univ Hosp, Pulm Dept, Mainz, Germany
[6] Univ Pittsburgh, Asthma Inst, Pittsburgh, PA USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷
关键词：
Treatments; Asthma; -; management; Severe asthma;
D O I：
10.1183/13993003.congress-2020.2259
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2259
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
    d'Ancona, Grainne
    Green, Linda
    Fernandes, Mariana
    Roxas, Cris
    Osman, Leyla
    Stewart-Knight, Kirsten
    Kavanagh, Joanna
    Nanzer-Kelly, Alexandra
    Jackson, David
    Kent, Brian
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [22] Treatment of patients with the hypereosinophilic syndrome with mepolizumab
    Rothenberg, Marc E.
    Klion, Amy D.
    Roufosse, Florence E.
    Kahn, Jean Emmanuel
    Weller, Peter F.
    Simon, Hans-Uwe
    Schwartz, Lawrence B.
    Rosenwasser, Lanny J.
    Ring, Johannes
    Griffin, Elaine F.
    Haig, Ann E.
    Frewer, Paul I. H.
    Parkin, Jacqueline M.
    Gleich, Gerald J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (12): : 1215 - 1228
  • [23] Mepolizumab for the treatment of severe eosinophilic asthma
    Poulakos, Mara N.
    Cargill, Shawna M.
    Waineo, Melissa F.
    Wolford, Allen L., Jr.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (13) : 963 - 969
  • [24] Characterising TMS-evoked EEG potentials for treatment response in people with epilepsy
    Dworkin, A.
    Jimenez-Jimenez, D.
    Turco, F.
    Johnson, C.
    Ravenscroft, C.
    Pizarro, J.
    D'Ambrosio, S.
    Silvennoinen, K.
    Zagaglia, S.
    Perulli, M.
    Sisodiya, S.
    Balestrini, S.
    EPILEPSIA, 2022, 63 : 231 - 232
  • [25] Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis
    Ennis, Daniel
    Lee, Jason Kihyuk
    Pagnoux, Christian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (07) : 617 - 630
  • [26] Mepolizumab for the Treatment of Eosinophilic Cystitis: Reply
    Trefond, L.
    Kahn, J. E.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2024, 34 (04)
  • [27] MEPOLIZUMAB AS AN EFFECTIVE TREATMENT IN CHILDHOOD EGPA
    De Guzman, D. Garcia
    Guzman, A.
    Hafed, Y.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S150 - S151
  • [28] Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis
    McBrien, C. N.
    Menzies-Gow, A.
    DRUGS OF TODAY, 2018, 54 (02) : 93 - 101
  • [29] Mepolizumab in the treatment of severe eosinophilic asthma
    Fainardi, Valentina
    Pisi, Giovanna
    Chetta, Alfredo
    IMMUNOTHERAPY, 2016, 8 (01) : 27 - 34
  • [30] Mepolizumab as Treatment for Chronic Eosinophilic Pneumonia
    Saeed, A.
    Reid, M.
    Chung, P. A.
    Warrior, K.
    Bemiss, B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345